betadine 100 mg/g unguent
egis pharmaceuticals plc - povidoni iodidum - unguent - 100 mg/g
iodura de potasiu serb 65 mg
astrea fontaine - franta - amoxicillinum iodidum - compr. - 65mg - alte preparate terapeutice preparate antidot
iodomarin comprimate 100 mcg
berlin-chemie ag (menarini group) - amoxicillinum iodidum - comprimate - 100 mcg
betadine 100 mg/g unguent
egis pharmaceuticals plc - povidoni iodidum - unguent - 100 mg/g
jodid 100
merck kgaa - germania - amoxicillinum iodidum - compr. - 100µg - iodoterapie iodoterapice
jodid 100 micrograme
merck healthcare kgaa - germania - amoxicillinum iodidum - compr. - 100micrograme - iodoterapie iodoterapice
iodomarin 200 200 mcg comprimate
berlin-chemie ag (menarini group) - amoxicillinum iodidum - comprimate - 200 mcg
iodomarin 100 100 mcg comprimate
berlin-chemie ag (menarini group) - amoxicillinum iodidum - comprimate - 100 mcg
amizoncic 10 mg/ml sirop
farmak sa - enisamii iodidum - sirop - 10 mg/ml
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - agenți antineoplazici - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.